Atossa Genetics Provides Breast Cancer Prevention Recommendations to the United States Preventative Services Task Force
February 04 2019 - 8:30AM
Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage
biopharmaceutical company developing novel therapeutics and
delivery methods to treat breast cancer and other breast
conditions, today announced that it has provided suggested changes
to the draft recommendation of the United States Preventative
Services Task Force (USPSTF) concerning “Breast Cancer: Medications
for Risk Reduction.” The public comment period ends February 11,
2019 and the finalized USPSTF recommendations will become available
in July 2019.
Atossa Genetics has proposed that the USPSTF recommendations
include the following additional guidance:
- Mammographic breast density (MBD) provides the only patient
level, biology-based assessment that is predictive of future breast
cancer and it is modifiable. All women undergoing mammography
should be informed of their breast density and its relationship to
breast cancer incidence, risk and mammographic
sensitivity.
- Tamoxifen, but not raloxifene or aromatase inhibitors, is
effective in reducing MBD and this reduction is associated with a
reduced risk of estrogen-receptor positive breast cancer.
“Atossa is dedicated to the prevention of breast cancer through
the use of mammography to identify women with MBD,” stated Dr.
Steven Quay, Chairman and CEO of Atossa Genetics. “There are over
3,400 peer-reviewed articles on the relationship between
mammographic breast density and the risk of future breast cancer.
Many states have laws that require that women be told their breast
density at the time they have a mammogram, as well as the impact a
high density has on both reducing the sensitivity of cancer
detection and increasing cancer incidence. Our recommended changes
are based on a substantial, peer-reviewed foundation of research
and, if accepted, should improve the utility of this widely used
guidance.”
Dr. Quay added, “It is our hope that when this recommendation is
updated in the future, Atossa’s proprietary Endoxifen, the active
metabolite of tamoxifen, will be the leading approach to reduce
breast density.”
You can leave your own comments for the USPSTF here: URL
for comment. The comment period ends February 11, 2019.
About United States Preventative Services Task
Force
Created in 1984, the USPSTF is an independent, volunteer panel
of national experts in prevention and evidence-based medicine. The
Task Force works to improve the health of all Americans by making
evidence-based recommendations about clinical preventive services
such as screenings, counseling services, and preventive
medications. All USPSTF recommendations are published on the Task
Force’s Web site and/or in a peer-reviewed journal.
Forward-Looking Statements
Forward-looking statements in this press release, which Atossa
undertakes no obligation to update, are subject to risks and
uncertainties that may cause actual results to differ materially
from the anticipated or estimated future results, including the
risks and uncertainties associated with actions and inactions by
the FDA, the outcome or timing of regulatory approvals needed by
Atossa, lower than anticipated rate of patient enrollment, higher
than anticipated drop-outs by study participants including because
of skin irritations in our Phase 2 MBD study, results of clinical
studies, the safety and efficacy of Atossa’s products and services,
performance of clinical research organizations and investigators,
obstacles resulting from proprietary rights held by others, such as
patent rights, and other risks detailed from time to time in
Atossa’s filings with the Securities and Exchange Commission,
including without limitation its periodic reports on Form 10-K and
10-Q, each as amended and supplemented from time to time.
Atossa Genetics Company Contact:
Kyle Guse CFO and General Counsel (O) 866 893-4927
kyle.guse@atossagenetics.com
Investor Relations ContactScott Gordon CorProminence LLC 377 Oak
Street Concourse 2 Garden City, NY 11530 Office: 516.222.2560
scottg@coreir.com
Source: Atossa Genetics Inc
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Sep 2023 to Sep 2024